SS-31

Mechanism

SS-31 is a small peptide that concentrates inside mitochondria, the energy factories of your cells, where it helps them produce energy more efficiently and protects them from damage. By stabilizing a key component of the mitochondrial membrane called cardiolipin, it can restore youthful energy production in aging or damaged cells. It is being studied for heart failure, kidney disease, and age-related mitochondrial decline.

Effects

## SS-31 (Elamipretide) — System-by-System Effects ### Mitochondrial Function (Primary Target) - **Cardiolipin stabilization**: SS-31 selectively binds cardiolipin in the inner mitochondrial membrane. Cardiolipin is essential for cristae structure, electron transport chain complex assembly, and cytochrome c anchoring. Damaged cardiolipin (from oxidative stress and aging) impairs all of these. SS-31 stabilizes cardiolipin and restores mitochondrial architecture. [Tier 1 — well-characterized mechanism, Szeto lab] - **Electron transport chain optimization**: By stabilizing cardiolipin, SS-31 improves complex I, III, and IV assembly and function. This reduces electron leak, decreases mitochondrial ROS production, and increases ATP output. [Tier 1] - **Mitochondrial membrane potential**: Restores optimal ΔΨm without causing hyperpolarization. This is important because both hypo- and hyperpolarization are pathological. [Tier 1] - **Cristae remodeling**: SS-31 treatment restores cristae morphology in aged and damaged mitochondria. Electron microscopy studies show dramatic structural improvement. [Tier 1 — published imaging studies] - **ROS reduction**: Unlike conventional antioxidants that scavenge ROS after production, SS-31 reduces ROS generation at the source by improving electron transport efficiency. This is a fundamental mechanistic advantage. [Tier 1] ### Cardiovascular System - **Heart failure**: Multiple clinical trials (TAZPOWER, PROGRESS-HF) evaluated elamipretide for heart failure with reduced ejection fraction (HFrEF). Results showed trends toward improvement in cardiac volumes but primary endpoints were not consistently met. [Tier 1 — Phase 2/3 RCT data, mixed results] - **Barth syndrome**: FDA granted elamipretide Breakthrough Therapy Designation for Barth syndrome, a rare X-linked mitochondrial cardiomyopathy caused by tafazzin mutations leading to cardiolipin deficiency. Phase 2 (TAZPOWER) showed improvements in 6-minute walk test and cardiac stroke volume. Phase 3 (TAZPOWER-Pivotal) showed improvement in 6MWT but with mixed statistical results depending on analysis population. [Tier 1 — this is the most advanced clinical program] - **Cardiac ischemia-reperfusion**: Preclinical data is very strong for cardioprotection during ischemia-reperfusion injury. SS-31 reduces infarct size by 40-60% in animal models when given before or during reperfusion. [Tier 2 — strong preclinical] - **Diastolic function**: Some evidence suggests SS-31 may improve diastolic dysfunction (HFpEF), which has very limited treatment options. [Tier 2] ### Kidney/Renal System - **Acute kidney injury**: Strong preclinical data for protection against ischemia-reperfusion kidney injury. SS-31 preserves mitochondrial function in renal tubular cells. [Tier 2] - **Chronic kidney disease**: Preclinical models show SS-31 slows CKD progression. Mechanism involves reduced tubular cell apoptosis and fibrosis. [Tier 2] ### Neurological System - **Neuroprotection**: SS-31 crosses the blood-brain barrier and concentrates in neuronal mitochondria. Preclinical evidence of neuroprotection in stroke, Parkinson, and Alzheimer models. [Tier 2] - **Cognitive aging**: Aged mice treated with SS-31 show improved spatial memory and reduced neuroinflammation. Mitochondrial function in hippocampal neurons is restored. [Tier 2] ### Musculoskeletal System - **Skeletal muscle aging**: SS-31 reverses age-related mitochondrial dysfunction in skeletal muscle. Aged mice treated with SS-31 show improved exercise capacity, muscle force generation, and mitochondrial respiration. [Tier 2 — Siegel et al., various publications] - **Muscle atrophy prevention**: May protect against disuse atrophy by maintaining mitochondrial quality during immobilization. [Tier 2] - **Exercise recovery**: Theoretical benefit for accelerating mitochondrial recovery after intense exercise. [Tier 3] ### Ophthalmic System - **Age-related macular degeneration (AMD)**: Clinical trials (ReCLAIM, ReCLAIM-2) evaluated elamipretide for dry AMD. ReCLAIM-2 did not meet primary endpoint but showed biological activity. Retinal mitochondrial dysfunction is a driver of AMD pathology. [Tier 1 — Phase 2 RCT data] - **Retinal ganglion cells**: Preclinical neuroprotection of retinal ganglion cells in glaucoma models. [Tier 2] ### Aging/Longevity - **Mitochondrial theory of aging**: SS-31 directly addresses the mitochondrial theory of aging by restoring mitochondrial function to more youthful levels. It does not just supplement a cofactor (like NAD+) — it physically restores the membrane architecture. [Tier 2 — strong mechanistic rationale] - **Cellular rejuvenation**: Some preclinical studies show SS-31 treatment reverses age-related changes in gene expression, not just mitochondrial function. This suggests upstream signaling effects. [Tier 2] - **Senescence**: May reduce senescent cell burden by improving mitochondrial quality control (mitophagy) and reducing mitochondrial-derived damage signals. [Tier 2-3]

Practitioner Guide

## SS-31 (Elamipretide) — Practitioner Guide ### Clinical Profile SS-31 (D-Arg-Dmt-Lys-Phe-NH2, also known as elamipretide or Bendavia) is a mitochondria-targeted tetrapeptide. It is the most clinically advanced mitochondrial therapeutic, with multiple Phase 2 and Phase 3 trials completed. Its unique mechanism — cardiolipin stabilization — distinguishes it from all other mitochondrial interventions. ### The Barth Syndrome Story (Important Context) Barth syndrome is a rare X-linked disorder caused by mutations in the tafazzin gene, which is required for cardiolipin remodeling. Patients develop cardiomyopathy, skeletal myopathy, neutropenia, and growth retardation. SS-31 was specifically developed as a potential treatment because it stabilizes cardiolipin. Clinical trial results: - **TAZPOWER (Phase 2)**: Showed improvements in 6-minute walk test (+39.3m vs. placebo, nominal p=0.024), cardiac stroke volume, and patient-reported fatigue. The trial was small (N=12). - **TAZPOWER-Pivotal (Phase 3)**: Results were more mixed. The ITT population showed improvement but some statistical analyses did not reach significance. The crossover design complicated interpretation. - **Compassionate use**: Multiple Barth patients on long-term elamipretide have shown sustained clinical improvement. Some families report transformative quality-of-life changes. - **Regulatory status**: Breakthrough Therapy Designation from FDA. The regulatory path has been complex due to the rarity of the disease and trial design challenges. ### Heart Failure Trials - **PROGRESS-HF (Phase 2)**: Elamipretide (4mg/day SC) did not meet primary endpoints for left ventricular end-systolic volume change in HFrEF patients. Some secondary endpoints showed trends. Disappointing for the field. - **Clinical perspective**: Heart failure is a massive market, and the negative trial results dimmed commercial enthusiasm. However, some cardiologists note that the patient population, dose, and duration may have been suboptimal. Mitochondrial-targeted therapy for HF remains biologically compelling. ### How Mitochondrial-Focused Practitioners Use SS-31 #### Typical Protocols (Off-Label/Research) - **Standard dose**: 5-40mg SC daily. Most practitioners start at 5mg and titrate to 20-40mg. - **Loading protocol**: 40mg SC daily for 4-8 weeks, then reduce to maintenance. - **Maintenance**: 5-20mg SC 3-5 days per week. - **Course-based**: Some practitioners use 6-8 week courses with 4-week breaks. #### Best Candidates (in Practitioner Experience) - Patients with documented mitochondrial dysfunction (organic acid testing, muscle biopsy) - Chronic fatigue syndrome / ME-CFS patients (mitochondrial dysfunction is a leading hypothesis) - Long COVID patients with persistent fatigue and exercise intolerance - Heart failure patients who have plateaued on standard therapy - Aging patients seeking comprehensive mitochondrial rejuvenation - Athletes looking for recovery optimization (more speculative) #### Real-World Observations - **Onset**: Many patients report improved energy within 3-7 days. This is fast for a structural intervention and may reflect rapid cardiolipin stabilization. - **Exercise tolerance**: Improvements in exercise capacity are among the most consistent findings. Patients report being able to do more without post-exertional malaise. - **Fatigue**: CFS/ME patients often report meaningful (not curative but meaningful) improvement in daily function. - **Cognitive clarity**: Some patients report improved mental clarity, potentially reflecting improved neuronal mitochondrial function. - **Injection tolerance**: SC injections are generally well tolerated. Mild injection site reactions are the most common side effect. ### Emerging Longevity Applications - **The aging mitochondria thesis**: Mitochondrial dysfunction is a hallmark of aging (Lopez-Otin et al., 2013, 2023). SS-31 is arguably the most targeted pharmacological intervention for this hallmark. - **Longevity stacking**: SS-31 + NAD+ (cofactor support) + urolithin A (mitophagy) + exercise (natural mitochondrial stimulus). This represents a comprehensive mitochondrial aging intervention. - **Preventive use**: Some longevity practitioners are beginning to use SS-31 preventively in 40-50 year olds before clinical mitochondrial decline becomes symptomatic. Evidence for this is Tier 3 at best. - **Comparison with other interventions**: SS-31 is mechanistically distinct from NAD+ (cofactor), PQQ (biogenesis), CoQ10 (electron carrier), and urolithin A (mitophagy). They address different aspects of mitochondrial health and are potentially synergistic. ### Combination Strategies - **Mitochondrial comprehensive**: SS-31 + NAD+ (IV or NMN) + CoQ10/ubiquinol + PQQ + urolithin A - **Heart failure adjunct**: SS-31 + CoQ10 (200-400mg) + standard HF medications - **CFS/ME protocol**: SS-31 + NAD+ (IV loading then NMN) + B vitamins + magnesium + pacing - **Longevity stack**: SS-31 + NAD+ + epitalon + GHK-Cu — addressing multiple hallmarks of aging ### Availability and Practical Considerations - Elamipretide is not yet FDA approved for any indication (as of 2026) - Available through research/compounding channels - Requires cold storage; peptide is relatively stable but should be reconstituted carefully - Cost is moderate for compounded versions; pharmaceutical-grade would be expensive - Compliance is good because patients typically feel improvement quickly ### Safety Profile - Very clean safety profile in clinical trials — no significant drug-related adverse events - Most common: injection site reactions (mild, transient) - No hepatotoxicity, nephrotoxicity, or hematological abnormalities in trials - Long-term safety data is accumulating from compassionate use and off-label use - Theoretical concern: altering mitochondrial membrane dynamics could have unforeseen effects with very-long-term use. No evidence of this so far.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No adequate human safety data during pregnancy. Mitochondrial-targeting peptide that alters cellular bioenergetics poses theoretical risk to fetal development and organogenesis.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Effects of mitochondrial-modulating peptide on nursing infant unknown.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Effects on developing mitochondrial physiology unknown.
  Action: Do not provide peptide protocols to individuals under 18.
• requires physician — Severe renal impairment
  Elamipretide is renally cleared. Patients with severe renal impairment (eGFR < 30) may accumulate the peptide to suprapharmacologic levels. Clinical trial data in severe renal disease is limited.
  Action: Requires nephrologist evaluation. Dose adjustment may be necessary. Monitor renal function during use.

Evidence

• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential

  Tung C, Varzideh F, Farroni E, Mone P, Kansakar U, Jankauskas SS, Santulli G (2025) — Int J Mol Sci — PMID: 39940712

  Elamipretide (SS-31/MTP-131/Bendavia) selectively binds cardiolipin in inner mitochondrial membrane, stabilizes cristae, reduces oxidative stress, enhances ATP production. Clinical trials show therapeutic potential in heart failure (PROGRESS-HF), mitochondrial disease (TAZPOWER, MMPOWER-3), and ischemia-reperfusion injury (ReCLAIM). Unique structure enables uptake across cell types with highly selective mitochondrial targeting.

  strong

• Post-sepsis chronic muscle weakness can be prevented by pharmacological protection of mitochondria

  Kingren MS, Keeble AR, Galvan-Lara AM, Ogle JM, Ungvari Z, St Clair DK, Butterfield TA, Owen AM, Fry CS, Patel SP, Saito H (2024) — Mol Med — PMID: 39563237

  SS-31 administered during acute sepsis effectively prevented post-sepsis skeletal muscle weakness development in aging mice (16-18 months). Mitochondrial abnormalities are the major causal factor in chronic post-sepsis muscle weakness. SS-31 protected mitochondrial function during sepsis, preventing the progressive weakness that develops after acute resolution. Supports SS-31 as mitochondrial protectant for sarcopenia/weakness prevention.

  moderate

• Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial

  Karaa A et al. (2023) — Neurology — PMID: 37268435

  Phase 3 randomized clinical trial in primary mitochondrial myopathy evaluating elamipretide over 24 weeks with co-primary outcomes including 6-minute walk distance and total fatigue on the PMMSA; useful for fatigue/exercise-tolerance discussions but not a clean broad efficacy win.

  moderate

• Elamipretide in Barth Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (TAZPOWER)

  Thompson WR, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ (2021) — Genetics in Medicine — PMID: 33495527

  Elamipretide (SS-31) improved 6-minute walk test distance and patient-reported outcomes in patients with Barth syndrome over 12 weeks. The mitochondria-targeted peptide stabilizes cardiolipin on the inner mitochondrial membrane, addressing the fundamental defect in Barth syndrome. Generally well-tolerated with injection site reactions as primary adverse event.

  moderate

• Effect of Elamipretide on Left Ventricular Function in Patients with Heart Failure with Reduced Ejection Fraction: Results of the PROGRESS-HF Phase 2 Trial

  Butler J, Khan MS, Anker SD, Fonarow GC, Kim RJ, Nodari S, O'Connor CM, Pieske B, Pieske-Kraigher E, Sabbah HN, Senni M, Voors AA, Zamani P, Zile MR, Gheorghiade M (2020) — JAMA Cardiology

  Elamipretide was evaluated in patients with stable heart failure with reduced ejection fraction (HFrEF). While well-tolerated, the trial did not meet its primary endpoint of improvement in left ventricular end-systolic volume. Secondary analyses showed trends toward improvement in some cardiac biomarkers. Mechanism targets mitochondrial cardiolipin stabilization to improve cellular energetics.

  moderate

Stacks featuring this peptide

Research Summary

## SS-31 (Elamipretide) — Research Summary ### Tier 1 (Strong Clinical Evidence) - **Mechanism of action**: Cardiolipin binding and stabilization is well-characterized through X-ray crystallography, NMR, and functional assays. The Szeto laboratory (Weill Cornell) has published extensively. This is among the best-understood peptide mechanisms. - **Barth syndrome**: Phase 2 (TAZPOWER, N=12) showed +39.3m improvement in 6MWT and improved cardiac stroke volume. Phase 3 results were more mixed statistically. Breakthrough Therapy Designation granted by FDA. - **Heart failure trials**: PROGRESS-HF (Phase 2, N=71) — elamipretide 4mg SC daily for 28 weeks did not meet primary endpoint (change in LVESV) but showed biological activity on some secondary endpoints. - **AMD trials**: ReCLAIM-2 did not meet primary endpoint in dry AMD. Some biological activity signals observed. - **Mitochondrial ROS reduction**: Demonstrated in multiple cell types and animal models. SS-31 reduces mitochondrial superoxide production by improving ETC efficiency rather than scavenging. - **Safety in clinical trials**: Clean safety profile across all completed clinical trials. No serious drug-related adverse events. ### Tier 2 (Moderate Evidence) - **Cardiac ischemia-reperfusion**: Extensive preclinical data showing 40-60% infarct size reduction in animal models. Highly reproducible across laboratories. - **Kidney protection**: Strong preclinical data for acute kidney injury and chronic kidney disease models. - **Skeletal muscle aging**: Aged mouse studies show restored muscle mitochondrial function, improved exercise capacity, and reversed age-related gene expression changes (Siegel, Campbell, Rabinovitch labs). - **Neuroprotection**: Preclinical evidence in stroke, Parkinson, Alzheimer, and traumatic brain injury models. Crosses BBB and concentrates in neuronal mitochondria. - **Aging reversal**: Studies showing SS-31 reverses age-related changes in multiple organ systems in mice. Gene expression profiling shows partial rejuvenation of aged transcriptomes. - **Cellular rejuvenation signals**: Beyond direct mitochondrial effects, SS-31 may influence retrograde signaling from mitochondria to nucleus, affecting broader cellular programs. ### Tier 3 (Emerging/Anecdotal) - **Off-label clinical use**: Growing practitioner experience with SS-31 for chronic fatigue, long COVID, and general longevity. Reports are generally positive. - **Longevity application**: Practitioners using SS-31 as part of comprehensive anti-aging protocols report patient satisfaction with energy and exercise tolerance improvements. - **CFS/ME**: Case reports and clinical observations of meaningful improvement in fatigue and exercise tolerance. No controlled trials in this population. - **Synergy with NAD+**: Theoretical and early clinical observation supporting combined mitochondrial therapy (SS-31 + NAD+). ### Key Research Gaps - Heart failure: Unclear if the Phase 2 results can be improved with different dosing, duration, or patient selection. - Barth syndrome: Regulatory path forward needs clarification given mixed Phase 3 statistics. - Longevity: No long-term aging studies in humans. Animal data is compelling but translation is uncertain. - Optimal dosing: Clinical trial doses (4mg/day) may be suboptimal. Practitioners using higher doses (20-40mg) report better results but this needs formal evaluation. - Combinations: No formal studies of SS-31 combined with other mitochondrial interventions.